EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy

Yuxuan Zhang, Zijing Zhou, Yuanyuan Rui, Fanhao Kong, Zhoubo Guo, Gang Zhao, Jun Wang, Jiacheng Li, Fangdong Zhao, Hui Huang, Fang Fang, Jiarui Zhang und 6 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04076-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuxuan Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laborator…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Esophageal Neoplasms, Biomarkers, Tumor, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Inner Mongolia Autonomous Region, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Esophageal squamous carcinoma (ESCC) is a common malignant tumor of the gastrointestinal tract with high morbidity and mortality rates. Lymphocyte activation gene-3 (LAG3), an important suppressive immune checkpoint in tumor immunity, exhibits a wobbling effect in the prediction of ESCC efficacy.

Methods

Tumor bite paraffin-embedded specimens from 84 patients diagnosed with ESCC, all of whom received radical concurrent chemoradiotherapy (CCRT) at our institution, were screened. For each tissue, we delineated the partitions and analyzed the spatial distribution of the tumor in an in situ immune microenvironment. The density and regional characteristics of immune factor-positive cells, together with the dynamics of various cells based on treatment regimens, were considered important factors influencing the prognostic significance of cancer.

Results

Compared with baseline tissues, the density of CD4 + and CD8 + T cells in the tumor microenvironment of the on-treatment tissues decreased, but the expression of IFN-γ in CD4 + and CD8 + T cells increased. The density of LAG3 positive cells was correlated significantly with the density of CD4 + and CD8 + T cells in both baseline and on-treatment tissues. The density of LAG3 + T cells and the rate of LAG3 positivity in activated CD4 + and CD8 + T cells were associated with elevated Ki67 expression. There was a significant correlation between high LAG3 expression and active CD4 + and CD8 + T cells in tumor cells. Elevated densities and tighter spatial relationships of both CD4 + and CD8 + T cells were associated with longer overall survival with ESCC.

Conclusion

Concurrent chemoradiotherapy without combined immunotherapy inhibited tumor-infiltrating T cells to a certain extent, and elevated immune checkpoint LAG3 was closely associated with immune activation in the ESCC tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyEsophageal NeoplasmsBiomarkers, TumorEsophageal Squamous Cell CarcinomaAntigens, CDHumansFemaleMaleMiddle AgedTumor MicroenvironmentLymphocyte Activation Gene 3 ProteinAgedPrognosisLymphocytes, Tumor-InfiltratingCD8-Positive T-LymphocytesCD4-Positive T-LymphocytesLymphocyte ActivationAdult

Stichwörter der Autor:innen

Concurrent radiotherapyEsophageal squamous carcinomaImmune checkpointLymphocyte activation gene-3 (LAG3)

Substanzen

Lag3 protein, humanBiomarkers, TumorLymphocyte Activation Gene 3 ProteinAntigens, CD

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center…
  • Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Canc…
  • Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, No. 12 Jian Kang Road, Shijiazhuang, 050010, Hebei, China.
  • Department of Radiation Oncology, Chifeng Tumor Hospital, Second Affiliated Hospital of Chifeng University, 45 Jiefang Street, Hongshan District, Chifeng, 024000, Inner Mongolia, China.
  • Department of Radiation Oncology, Chifeng Tumor Hospital, Second Affiliated Hospital of Chifeng University, 45 Jiefang Street, Hongshan District, Chifeng, 024000, Inner Mongolia, China. zhenpeng0918@163.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Inner Mongolia Autonomous Region
  • State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine

Zitieren

APA

Zhang, Y., Zhou, Z., Rui, Y., Kong, F., Guo, Z., Zhao, G., Wang, J., Li, J., Zhao, F., Huang, H., Fang, F., Zhang, J., Zhang, T., Zhang, W., Wang, P., Chen, X., Zhen, P., & Pang, Q. (2025). LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04076-2

Vancouver

Zhang Y, Zhou Z, Rui Y, Kong F, Guo Z, Zhao G, et al. LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04076-2

BibTeX
@article{Zhang2025,
  author = {Zhang, Yuxuan and Zhou, Zijing and Rui, Yuanyuan and Kong, Fanhao and Guo, Zhoubo and Zhao, Gang and Wang, Jun and Li, Jiacheng and Zhao, Fangdong and Huang, Hui and Fang, Fang and Zhang, Jiarui and Zhang, Tian and Zhang, Wencheng and Wang, Ping and Chen, Xi and Zhen, Peng and Pang, Qingsong},
  title = {LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04076-2}
}
Kostenlos starten →